PRS43 Influence of Demographic Status on Outcomes In Copd Patients: A Prospective Study  by A, S. et al.
A176  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
teen of the most disabling conditions as reported by the Centers for Disease Control 
were also collected. Overall work and activity impairment estimates were calculated 
for both the full sample and each of the nineteen diagnoses. Results: In total, 
50.7% of survey respondents were employed and provided information with respect 
to their work impairment; all respondents regardless of employment reported their 
activity impairment. These adults were an average 44.20 years old (SD= 13.52) and 
52.6% were male. The mean level of absenteeism, presenteeism, overall work impair-
ment, and activity impairment was 3.49%, 12.91%, 15.01%, and 22.08%, respectively 
(SDs= 13.88%, 21.98%, 24.96%, and 28.33%, respectively). The highest levels of over-
all work impairment were observed for patients with AIDS (42.7%), broken bones 
(36.6%), and hernia or rupture (32.8%) whereas the highest levels of activity impair-
ment were observed for patients with a hernia or rupture (53.9%), kidney problems 
(48.5%), and back or spine problems (47.5%). ConClusions: These results help to 
provide some context for work and activity impairment by providing estimates for 
the overall population as well as for nineteen separate disease states/conditions.
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objeCtives: The asthma quality of life questionnaire (AQLQ) is a condition-spe-
cific measure which evaluates four domains of health-related quality of life (HRQL) 
important in asthmatic adults: activity limitation, symptoms, emotional function, 
and environmental exposure. The objectives of this study were to identify: 1) How 
many HRQL claims were obtained in the label of asthma products using the AQLQ; 
2) HRQL measures used in trials but not mentioned in label; and 3) Reasons why 
to discard these measures. Methods: The PROLabels database was searched on 
12/27/2014 using “asthma” as a key word for therapeutic indication. Results: Out 
of thirty-seven products approved for asthma (five by the EMA, and 32 by the FDA), 
twenty-five had PRO claims in their label. Five of them had a HRQL claim: Symbicort 
(budesonide/formoterol fumarate dehydrate - FDA), Advair HFA (fluticasone propi-
onate/salmeterol xinafoate - FDA), Advair Diskus (fluticasone propionate/salme-
terol xinafoate - FDA), Dulera (mometasone furoate/formoterol fumarate – FDA) 
and Xolair (omalizumab - EMA). In all cases, the HRQL evaluation was performed 
using the AQLQ. Of the 20 products with PROs in label (but not HRQL), seven had 
no HRQL evaluation performed, three had no medical review available, and ten 
had a HRQL evaluation using the AQLQ (n= 8), and/or the SF-36 (n= 3) [one product 
used both measures]. The main reasons provided for not including HRQL data in 
the label were lack of statistical significance between treatment groups, or not 
reaching clinical significance. In one case (omalizumab), the FDA argued about the 
improper use of the AQLQ. ConClusions: This review has shown that all HRQL 
claims in asthma product labels were obtained using the AQLQ, a validated measure 
in asthma patients with a recognized minimally important difference enabling a 
clear interpretation of results. For these reasons the AQLQ could be considered as 
a potentially acceptable measure for regulatory qualification.
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objeCtives: To examine the relationships between health-related quality of life and 
use of Internet for health related activities among patients with asthma. Methods: 
The 2009 National Health Interview Survey and 2010 Medical Expenditure Panel 
Survey were used to select the study sample; 523 adult patients with asthma (n= 
6,075,087 weighted). Health-related quality of life was the outcome of interest. The 
Andersen Model of Health Care Utilization was used to guide the selection of inde-
pendent variables. Predisposing factors, enabling factors, need factors, smoking 
status, and health-related Internet activities comprised the independent variables. 
Five health-related Internet activities included 1) seeking health information on the 
Internet, 2) use online chat group to learn about health, 3) refill a prescription on the 
Internet, 4) schedule an appointment with a health care provider using the Internet, 
and 5) communicate with a health care provider over email. Linear regression 
analyses, incorporating the sampling weights, were employed. All analyses were 
conducted using STATA (version 13.1). Results: Fifty percent of asthma patients 
reported performing at least one health-related Internet activity. The most reported 
activity was seeking health information on the Internet (49%). Mean physical com-
ponent summary (PCS-12) and mental component summary (MCS-12) in asthma 
patients were 49.52 (SD= 0.62) and 50.5 (SD= 0.52). After controlling for independent 
variables, only scheduling an appointment with a health care provider using the 
Internet was significantly related to the physical component summary score (β = 4.94, 
95% CI: 0.95 to 8.94). ConClusions: Study Results suggest that the Internet plays a 
role in self-care and health-related quality of life among asthma patients. However, 
findings also indicate that asthma patients haven’t fully implemented using the 
Internet to accomplish all self-care tasks. Future research should examine the rela-
tionships between health-related Internet activities, health services utilization and 
outcomes.
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objeCtives: Our study was aimed to assess the Influence of Demographic 
status on outcomes such as pulmonary function, medication adherence and 
health related quality of life (HRQoL) in COPD patients Methods: An open 
which influence the treatment outcome in TB patients. ConClusions: The present 
study concluded that majority of the TB patients had successful treatment out-
come, however, efforts should be made evaluate the treatment failure particularly 
in elderly patients to achieve better treatment outcomes.
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Patients with COPD experience lower levels of health related quality of life (HRQoL). 
Social and emotional support has been found to improve mental and physical 
health and reduce mortality. Few studies have investigated the impact of social 
and emotional support among patients with COPD. objeCtives: To examine the 
impact of social and emotional support on HRQoL, disability and depression among 
COPD patients. Methods: We utilized data from the 2013 Behavioral Risk Factor 
Surveillance System (BRFSS) to match self-reported COPD patients who receive 
emotional/social support (63%) with those who rarely/never (37%) receive that sup-
port based on a propensity score model. We used the STATA command psmatch2 
to perform 1:1 nearest neighbor matching without replacement, and caliper width 
was set at 0.01. Adequacy of matching was assessed by estimating the standardized 
differences between the matched pairs for all variables. We compared the HRQoL 
domains (general, physical, mental health and activity limitation), depression and 
disability for the matched cohort using the McNemar’s test. Results: After pro-
pensity score matching, standardized differences between groups were < 10% for all 
matched variables (demographics, smoking, exercise, and comorbidities), indicat-
ing adequate matching between each level of emotional support. COPD patients 
who rarely/never receive emotional/social support were more likely to experience 
more poor physical HRQoL days (n= 307 pairs, odds ratio (OR)= 2.13, 95% confidence 
interval (CI):1.52-3.03, p< 0.001), poor mental HRQoL days (n= 300 pairs ,OR= 1.59, 
CI:1.11-2.72, p= 0.007), days of activity limitations (n= 319 pairs, OR= 1.92, CI:1.4-2.7, 
p< 0.001) and depression (n= 321 pairs, OR= 1.59, CI:1.1-2.33, p < 0.001). Poor gen-
eral health and disability were not significantly associated with emotional/social 
support. ConClusions: Among COPD patients, inadequate emotional and social 
support is associated with depression and impairments of most HRQoL domains. 
Recognition of the importance of emotional and social support by family members, 
healthcare providers and policy makers is important to improve functioning among 
COPD patients.
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objeCtives: Chronic urticaria (chronic hives) can be inducible or spontaneous 
(CSU). Data supporting the impact of CSU on patients and comparisons with other 
dermatological diseases are scarce. This study evaluated the burden of illness 
associated with CSU relative to psoriasis (PsO) among adults across 5 European 
countries (EU) and the United States (US). Methods: Data from respondents with 
a diagnosis of chronic hives (as proxy for CSU) or PsO were collected from the 
National Health and Wellness Survey (NHWS) in the EU (2010-2013) and US (2010-12). 
Humanistic burden was measured using SF-12v2 (2010-11) or SF-36v2 (2012-13) and 
health utility score (SF-6D). Self-reported anxiety, depression and sleep difficulty 
were also assessed. Comorbidity was measured using Charlson Comorbidity Index 
(CCI). Bivariate analysis (t-tests for continuous and chi-square tests for categorical 
variables) was used to compare CSU patients vs. PsO patients in EU and US, respec-
tively. Results: Study included 1,516 patients with CSU (769 EU; 747 US) and 12,964 
patients with PsO (7,857 EU; 5,107 US). CSU patients had lower (worse) mean mental 
(40.8 vs. 44.6) and physical component scores (45.2 vs. 47.4) and SF-6D score (0.64 
vs. 0.69), than PsO patients (p< 0.001 for all) in EU. Lower scores for CSU patients 
were also reported in US (44.7 vs. 47.0, 43.8 vs. 45.5 and 0.67 vs. 0.70, respectively, 
p< 0.001 for all). More CSU than PsO patients reported anxiety (45.4% vs.30.4%), 
depression (26.9% vs. 20.4%) and sleep difficulties (55.7% vs. 42.6%) both in EU and 
US (41.6% vs. 30.4%, 38.8% vs. 27.7%, and 49.9% vs. 40.3%, respectively) (p< 0.001 for 
all). Comorbidity burden was higher for CSU than PsO in EU (CCI= 0.90 vs. CCI= 0.50, 
respectively) and US (CCI= 1.05 vs. CCI= 0.78) (both, p< 0.001). ConClusions: CSU 
is associated with significant detrimental impact on quality of life comparable or 
greater burden relative to PsO in EU and US.
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objeCtives: Work and activity impairment represent important dimensions for 
assessing the burden of disease. However, unlike some other patient-reported out-
come measures, there are no population norms for work and activity impairment 
or studies that extensively compare impairment across conditions. The inability 
to compare against the broader population or to specific diseases or conditions 
can make it difficult for researchers to put the effect of a disease on impairment 
in a broader context. Methods: Data came from the 2012 United States National 
Health and Wellness Survey (NHWS), a health survey of a nationally representative 
sample of adults (N= 71,141). The NHWS includes the Work Productivity and Activity 
Impairment (WPAI) questionnaire, which measures absenteeism, presenteeism, 
overall work impairment, and activity impairment. Self-reported diagnoses of nine-
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objeCtives: Studies have demonstrated the importance of the environment both 
on the development of asthma and on exacerbation of asthma symptoms in those 
who have been diagnosed with the disease. The goal of this project was to pro-
vide in-home asthma services that covered both self-management education and 
home environmental interventions for children diagnosed with asthma living in 
Section 8 Multi-family Housing. Methods: This HUD-funded project consisted 
of 3-4 home visits by a public health nurse over a one year period—an in-home 
baseline visit; a visit to deliver allergen-reducing products if needed; and 6 and 
12-month follow-ups by phone or in-home visit. Data was collected on asthma 
status (health-related quality of life and asthma control), health service utilization 
(hospitalizations, ED and office visits) and school and/or work absences due to 
asthma. Data analysis was completed using SAS v9.3. Results: 219 children from 
161 low income families were enrolled from five participating local public health 
agencies in a large metropolitan area. The low cost interventions provided, resulted 
in significant increases in the proportion of enrollees experiencing minimal to no 
daytime and nighttime symptom burden and functional limitations at the 12-month 
follow-up (p< 0.05). Overall health care service use declined. There was a significant 
reduction in school days missed (p< 0.05), the equivalent of 5 school days per child 
per year. The average cost per family of interventions, was $424 (e.g. mattress and 
pillow encasements, HEPA vacuum cleaners, air purifiers). Program administra-
tive costs per family were $585 (e.g. enrollment costs, travel time, visit time and 
documentation). ConClusions: This study provided additional support for the 
usefulness and success of providing home interventions for low income children 
who have been diagnosed with asthma. Low cost, targeted interventions led to 
improvements in HRQOL, decreased health service utilization, increased school 
attendance and a positive return on investment.
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objeCtives: The aim of our study was to analyze the generic competition of medica-
ments containing the active substance montelukast sodium and to examine the 
cost-containment methods of the Hungarian National Health Insurance Fund 
Administration. Methods: Data derived from the nationwide pharmaceutical 
database of Hungarian National Health Insurance Fund Administration (2007-2013). 
We analyzed the turnover and price of the medicaments containing the active sub-
stance montelukast sodium. Accordingly our indicators were: consumer price, social 
insurance subsidy, patients’ co-payment and defined daily dose (DOT). Results: 
The price of Singulair 10 mg tablets was 32 USD in October 2011, when the generics 
appeared, and it was reduced to 10 USD by the end of 2013. The generics started 
with a price 40% lower (for example Montelukast Teva 10 mg tablets: 19 USD, Eonic 
10 mg tablets: 17 USD, Montelukast Sandoz 10 mg tablets: 19 USD), their price was 
diminished below 7.4 by the end of 2013 (for example: Montelukast Teva 10 mg tablets: 
5.2 USD, Eonic 10 mg tablets: 5.8 USD, Montelukast Sandoz 10 mg tablets: 5.5 USD). 
The DOT increased gradually: In 2007 it was 1.7 million days, in 2010 6.3 million days 
and in 2013 it increased over 10 million days. The amount of the health insurance 
subsidy was 9.2 million USD in 2010. It reached its peak in 2011 (10.5 million USD) , in 
2012 it was reduced to 7 million USD, in 2013 to 4.1 million USD, in all it is a setback 
of 61%. ConClusions: Following the introduction of generic drugs, the price of the 
medicaments containing montelukast sodium was significantly reduced. The annual 
health insurance subsidy was significantly reduced as well, while the DOT increased. 
The patients’ access to drugs containing montelukast sodium increased significantly.
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objeCtives: Chronic obstructive pulmonary disease (COPD) is one of the most 
common lung diseases. COPD prevalence among US adults was estimated to be 
15 million or 6.3 percent of the total population in 2011. Nonadherence to COPD 
maintenance medications has been reported to be associated with more hospitaliza-
tions, higher mortality and lower quality of life. This study examined COPD mainte-
nance medication adherence among Medicare beneficiaries with COPD. Methods: 
An observational, retrospective cohort study was conducted using 2007 and 2008 
Medicare Current Beneficiary Survey (MCBS) data. Sample inclusion criteria were 
being diagnosed with COPD and having at least two Medicare Part D claims. 
Medication adherence was measured by calculating proportion of days covered 
(PDC). PDC was calculated as the number of days with COPD maintenance medica-
tions available divided by total number of days in a six-month period following 
index dates, which were defined as the date of first COPD maintenance medica-
tion fill in 2007. A dichotomous variable was used to determine adherence status. 
Individuals with PDCs of 0.80 or greater were considered adherent and individuals 
with PDCs less than 0.80 were considered nonadherent. Logistic regressions were 
used to examine associations between demographic variables and medication 
adherence. Results: A total of 292 beneficiaries fulfilled sample selection criteria 
and were included in the analysis. The mean age was 72 years, 54 percent were ≤ 
75 years old and 11 percent were 85 years or older. The sample was predominantly 
female (60%) and white (85%). The mean±standard deviation PDC was 0.69±0.24. 
More than half (59%) of the Medicare beneficiaries had PDC of less than 0.80 and 
were classified as nonadherent to their COPD maintenance medications. No sig-
label prospective study was conducted among 208 COPD patients who were 
admitted in a tertiary care teaching hospital in south India after obtaining the 
ethical clearance. Demographics, medication adherence and quality of life 
of the patients were measured using Morisky scale (Adherence) & St. George 
Respiratory Questionnaire (HRQoL). Statistical analyses were performed using 
SPSS®version 20. Results: Mean age of the study population (n= 208) was 
58.42±9.72.(Males = 93.5%) . After the drug treatment, males showed statistically 
significant (p < 0.05) improvement in pulmonary function, medication adher-
ence and HRQoL. Patients with COPD duration of < 5 years showed a signifi-
cant improvement in pulmonary function and HRQoL scores. Literate patients 
had a significantly higher improvement in Medication Adherence and HRQoL 
than illiterate patients. ConClusions: The results of the study suggest that 
demographic factors were independently associated with outcomes in COPD 
patients.
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objeCtives: Tobacco smoking is the leading cause of preventable morbidity 
and mortality in the United States, and smoking cessation has multiple health 
benefits. The purpose of this study was to assess cigarette smokers’ preference 
towards characteristics of tobacco cessation medications using a Willingness-to-Pay 
approach. Methods: Data from the 2008 Healthstyles Survey, a mail-based prob-
ability sample of 5,399 adult aged ≥ 18 years, were used to assess three primary out-
comes among current cigarette smokers (n= 914): 1) interest in quitting; 2) interest 
in using cessation medications; and 3) willingness to pay for six types of cessation 
medications. Point estimates and 95% confidence intervals were calculated overall 
and by sociodemographic and smoking behavior characteristics. Multivariate Probit 
regression analysis was used to evaluate smokers’ willingness to pay in relation 
to perceived importance of three cessation medication characteristics: conveni-
ence of use, over-the-counter availability, and efficiency to help quit. All models 
controlled for sociodemographic characteristics, smoking behavior characteristics, 
and U.S. region fixed effects. Results: Approximately 68.4% of current cigarette 
smokers were interested in quitting. Among these individuals, 45.6% indicated that 
they were interested in using cessation medications, and of these, 47.3% indicated 
that they were willing to pay $150 or more out-of-pocket for these medications. 
Convenience of use and the effectiveness of these medications to help quit were 
positively associated with current smokers’ willingness to pay for $300 or more 
(p≤ 5%); however, no association was observed for over-the-counter availability. 
Self-reported exposure to telephone quitline advertisements was also positively 
associated with the willingness-to-pay. ConClusions: Approximately 68% of cur-
rent smokers are interested in quitting and about half of those smokers interested 
in quitting are also interested in using cessation medications. Convenience of use 
and the medication’s effectiveness are important to smokers with quit intentions. 
Understanding these preferences may help inform efforts to increase access and 
utilization of cessation medications.
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objeCtives: Allergic asthma (AA) patients comprise over 93% of severe/difficult 
to treat cases in the US and patients face a lifelong treatment course. A dearth of 
real world information exists on the use of effective and approved treatments, 
particularly among adolescents. This study examined medication treatments for 
AA patients and incorporated treatment intensity (HighTx), consistent with NHLBI 
treatment guidance (steps 5-6), as a severity proxy. Methods: This retrospec-
tive, observational study used MarketScan claims to identify newly diagnosed 
AA patients (10/2009 – 9/2012). Two cohorts were established: adolescents (12-17); 
adults (18-64). Index was the date of first AA diagnosis. Continuous enrollment 
was required for 12 months before and after index. Demographics and comorbidi-
ties were measured at baseline. Asthma medication use was observed in the 12 
months after index. HighTx was characterized for patients with high dose inhaled 
corticosteroid/long-acting beta agonist (ICS/LABA) combination treatment and 
having > 30 days supply in any continuous treatment period in 12 months after 
index. Results: Gender distribution differed across age cohorts (adolescents: 
> 50% female; adults: > 65% male). Acute illness drove comorbidity burden: more 
adolescents experienced acute respiratory infections (37.9% vs. 24.5% adult); more 
adults reflected acute sinusitis (20.6% vs. 25.2% adult). Treatment patterns (full 
sample): more adolescents received short-acting beta agonist (35.5% vs. 30.2% 
adults); fewer received ICS/LABA (22.6% vs. 34.5% adults) and monoclonal anti-
bodies (0.3% vs. 1.1% adults). Treatment pattern (HighTx): more patients received 
ICS/LABA (adolescents 98.9%; adults 99.3%); days on therapy did not exceed 160 
(ICS/LABA) for either HighTx age cohort. Twice as many HighTx adults received 
monoclonal antibodies as adolescents (2.5% vs. 5.1% adults). ConClusions: In 
light of similar disease burden, AA diagnosis, and availability of effective treat-
ments, fewer AA adolescents received targeted therapies than adults. This dispar-
ity highlights the opportunity to incorporate targeted therapies as a treatment 
option, particularly for adolescent AA patients.
